Skip to main content

Table 2 Tuberculosis patients’ loss to follow-up status by selected base line socio-demographic and clinical characteristics of 1341 TB patients enrolled into TB treatment and care at public health facilities, rural Ethiopia, during 2008–2015

From: Does time to loss to follow-up differ among adult tuberculosis patients initiated on tuberculosis treatment and care between general hospital and health centers? A retrospective cohort study

Characteristics

Category

Follow-up outcome

LTFU n (%)

Censored n (%)

Age

Continuous

122 (9.1)

1219 (90.1)

Sex (n = 1341)

Male

83 (6.2)

704 (52.5)

Female

39 (2.9)

505 (37.7)

Residence (n = 1341)

Urban

66 (4.9)

838 (62.5)

Rural

56 (4.2)

380 (28.3)

Patient category (n = 1341)

New

106 (7.9)

1056 (78.7)

Relapse

4 (0.3)

31 (2.3)

Failure

0 (0)

3 (0.2)

Transferred in

12 (0.9)

129 (9.6)

Distance (n = 1340)

≤10 km

73 (5.4)

1071 (79.9)

> 10 km

49 (3.7)

147 (11.0)

Drug intensive (n = 1341

RHZE

120 (8.9)

1210 (90.3)

RHZ

2 (0.1)

9 (0.7)

Drug continuous (n = 1322)

EH

47 (3.6)

410 (31.0)

EH and RH

2 (0.2)

33 (2.4)

RH

65 (4.9)

765 (57.9)

CPT provision at enrolment (n = 230)

Yes

19 (8.3)

182 (79.1)

No

6 (2.6)

23 (10.0)

TB type (n = 1341)

P/pose

47 (3.5)

416 (31.0)

P/negative

51 (3.8)

459 (34.2)

EP

24 (1.8)

344 (25.7)

Treatment phase (n = 1341)

Intensive

85 (6.3)

99 (7.4)

Continuous

41 (3.1)

1116 (83.2)

HIV sero status (n = 1341)

Reactive

36 (2.7)

196 (14.6)

Non-reactive

85 (6.3)

1022 (76.2)

ART linkage status (n = 234)

On ART

12 (5.1)

170 (72.6)

Not on ART

19 (8.1)

33 (14.1)

Type of health facility (n = 1341)

Health center

84 (6.3)

530 (39.5)

Hospital

38 (2.8)

689 (51.4)

  1. ART anti-retroviral therapy, CPT cotrimoxazole prophylaxis therapy, HIV human immune virus, TB tuberculosis, RHZE rifampicin + isoniazid + pyrazinamide + ethambutol, EH ethambutol